Navigation Links
China Health Resource, Inc. Defers Implementation of Reverse Stock Split in Light of Continuing Market Volatility
Date:4/9/2009

SUINING CITY, Sichuan Province, P.R. China, April 9, /PRNewswire-FirstCall/ -- China Health Resource, Inc. (OTC Bulletin Board: CHRI), a Delaware corporation, announced today that its Board of Directors (the "Board") has decided to defer immediate implementation of a reverse stock split of the Company's Class A common stock at this time in light of the continuing volatility in the global capital markets. The Board considers that the current market instability would undermine the purpose and intent of the action. The Company and the Board will continue to monitor and analyze market conditions, as well as other strategic opportunities that may become available to the Company in order to achieve its financial objectives and to increase shareholder value. The Board has reserved the discretion to implement the reverse stock split at a future date or not at all.

On February 17, 2009, in accordance with Delaware corporate law, the holders of a majority of the outstanding shares of our common stock executed a written consent approving a number of proposals, including the reverse stock split, which consent became effective on April 4, 2009. An Information Statement, dated March 12, 2009 was filed with the SEC and provided to shareholders describing the various proposals subject to the stockholder consent. These proposals included (i) election of members of the Board of Directors; (ii) ratification of the Company's auditors for fiscal year 2009; (iii) certain amendments to the Company's Certification of Incorporation to, among other things, reduce the par value of the Class A common stock, eliminate the Class B common stock, and provide for blank check preferred stock; and (iv) adoption of a stock option incentive plan for directors, officers, employees and consultants of the Company. The amendments to the Company's Certification of Incorporation will become effective upon the applicable filing with the Secretary of the State of Delaware. A copy of the definitive Information Statement may be obtained from the SEC's website at www.sec.gov or the Company's website at www.chriglobal.com.

About China Health Resource

China Health Resource engages in the development and commercialization of the Dahurian Angelica Root ("DAR"), a popular traditional Chinese medicine, in the People's Republic of China. DAR is a popular herb employed extensively as an ingredient in food, medicine, and cosmetics and is used for the treatment of pain, swelling, and pustule. In addition, the Company sells DAR-related products, which include the Bai Ling Capsule, Yi Shen Capsule, DAR slices, and DAR scent bag through regional distributors throughout the People's Republic of China. For more information, visit http://www.chriglobal.com/.

Safe Harbor and Forward-Looking Statements

Certain statements found in this document, including statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These forward-looking statements include statements of management's plans and objectives for our future operations. Actual results and developments could differ materially from those expressed in or implied by such statements due to a number of factors, including, without limitation, those described in the context of such forward-looking statement, our expansion and acquisition strategy, our ability to achieve operating efficiencies, our dependence on network infrastructure, capacity, telecommunications carriers and other suppliers, industry pricing and technology trends, evolving industry standards, domestic and international regulatory matters, general economic and business conditions, the strength and financial resources of our competitors, our ability to find and retain skilled personnel, the political and economic climate in which we conduct operations and the risk factors described from time to time in our other documents and reports filed with the SEC. Additional factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to: (1) our ability to successfully develop, manufacture and deliver DAR and related products on a timely basis and in the prescribed condition; (2) our ability to compete effectively with other companies in the same industry; (3) our ability to raise sufficient capital in order to effectuate our business plan; and (4) our ability to retain our key executives. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission, including our reports on Forms 10-K, 10-KSB, and 10-Q and the foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE China Health Resource, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Chinas 1-child policy could backfire on its elderly
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
9. Supplier Assessments to Help Buyers Identify Reliable China Exporters
10. Study shows lead-based paint problem isnt isolated to China
11. Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... ... a new educational seminar to focus on current legislative activity and the latest ... begin at 1 p.m. Sunday, Sept. 10, and will continue through Monday, Sept. ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, ... NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware SDI ... diagnostic device operations. With this platform, initializing devices and importing studies are just ...
(Date:5/26/2017)... ... May 26, 2017 , ... Boar’s Head Brand®, one of ... Memorial Day entertaining that are sure to satisfy your guests’ flavor cravings, while ... and cheeses featured in these refreshingly balanced recipes are packed with flavor, creating ...
(Date:5/26/2017)... , ... May 26, 2017 , ... On May 24, ... which narrowly passed the U.S. House on May 4, would result in 23 million ... under continued implementation of the 2010 Patient Protection and Affordable Care Act (ACA). ...
(Date:5/26/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... the Peace Agreements being discussed by President Donald Trump and the rest of the ... to speed up peace talks in the continuous battle between Israel and Palestine. The ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017 CSSi, the global ... the clinical research industry, is proud to announce the ... The new website features both enriched content and a ... and enhances the company,s already well-established position as the ... "After many months of hard work, we ...
(Date:5/9/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... on the development of oral drug delivery systems, ... has granted Oramed a patent titled, "Methods and ... covers Oramed,s invention of an oral glucagon-like peptide-1 ... hormone that stimulates the secretion of insulin from ...
(Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
Breaking Medicine Technology: